sur Cherry SE (isin : DE000A3CRRN9)
Cherry SE: SmartLink Product Approval is Imminent
Munich, 17 September 2024 - Cherry SE has announced the imminent product approval of CHERRY SmartLink. This product is currently in the final testing phase by external partners and the approval body to ensure product safety.
The market for CardLink solutions is competitive, with various factors influencing the launch such as technical implementation, pricing, and pharmacies' purchase commitments. CHERRY's business model charges only for actual transactions, aiming to create long-term benefits for all stakeholders.
Cherry SE CEO Oliver Kaltner highlighted the importance of expanding business models with recurring revenue. He emphasized that CHERRY SmartLink embodies the digitalization of healthcare, offering a patient-oriented, data-secure digital solution with robust safety and quality standards.
CHERRY SmartLink is a SaaS solution allowing NFC-enabled smartphones to function as eHealth card terminals. This new offering facilitates secure e-prescription redemption via CardLink, integrating an approved interface into apps for seamless use.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Cherry SE